Bioenergetics breakdown in Alzheimer's disease: Targets for new therapies

International Journal of Physiology, Pathophysiology and Pharmacology

Volumn 3, Issue 2, 2011, Pages 133-139

  Saxena, Uday ^a  

^a Kareus Therapeutics   (Switzerland)

Author keywords

Alzheimer's disease; Amyloid hypothesis; Neuronal energy; New therapeutics

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; BETA SECRETASE 1; CYTOCHROME C OXIDASE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; HEXOKINASE; KETONE; NEUROTRANSMITTER; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXOGLUTARATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE; SECRETASE; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; BIOENERGY; BRAIN HYPOXIA; BRAIN OXYGEN CONSUMPTION; COGNITIVE DEFECT; CYTOKINE PRODUCTION; DRUG TARGETING; ELECTRON TRANSPORT; ENERGY YIELD; ENZYME ACTIVITY; GENETICS; GLUCOSE BRAIN LEVEL; GLYCOLYSIS; HUMAN; METABOLIC DISORDER; MYELINATION; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROTOXICITY; NEUROTRANSMISSION; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; STROKE; TRAUMATIC BRAIN INJURY;

EID: 79960116146     PISSN: None     EISSN: 19448171     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20:154-159
2. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81:741-766
3. Saxena U. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here? Expert Opinion Therapeutic Targets 2010; 14(12):1273-1277
4. De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010; 6(2): 99-107.
5. Struble RG, Ala T, Patrylo PR, Brewer GJ, Yan XX. Is brain amyloid production a cause or a result of dementia of the Alzheimer's type? J Alzheimers Dis 2010; 22(2): 393-399.
6. Ferreira IL, Resende R, Ferreiro E, Rego AC, Pereira CF. Multiple defects in energy metabolism in Alzheimer's disease. Curr Drug Targets 2010; 11(10): 1193-1206.
7. Reddy VP, Zhu X, Perry G, Smith MA. Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis 2009; 16(4): 763-774.
8. SAXENA U. NATURE INDIA. IS ALZHEIMER'S A LIFESTYLE DISEASE? DOI: 10.1038/NINDIA.2011.10; PUBLISHED ONLINE 31 JANUARY 2011
9. Costantini LC, Barr LJ, Vogel JL, Henderson ST. Hypometabolism as a therapeutic target in Alzheimer's disease. BMC Neurosci 2008; 9 Suppl 2:S16.
10. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetics deficit precedes alzheimer's pathology in female mouse model of alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106(34): 14670-14675.
11. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann NY Acad Sci 2008; 1147:180-195
12. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, Pirraglia E, De Santi S, Reisberg B, Wisniewski T, de Leon MJ. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009; 36(5): 811-822
13. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005; 32(4): 486-510.
14. Braidy N, Guillemin G, Grant R. promotion of cellular NAD(+) anabolism: therapeutics potential for oxidative stress in ageing and Alzheimer's disease. Neurotox Res 2008; 13(3-4): 173-184.
15. Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM, Swanson RA.NAD+ depletion is necessary and sufficient for poly (ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 2010; 30(8):2967-2978.
16. Liguri G, Taddei N, Nassi P, Latorraca S, Nediani C, and Sorbi S. Changes in Na□,K□-ATPase, Ca2□-ATPase and some soluble enzymes related to energy metabolism in brains of patients with Alzheimer's disease. NeurosciLett 1990; 112:338-342.
17. Sims NR, Blass JP, Murphy C, Bowen DM, and Neary D. Phospho-fructokinase activity in the brain in Alzheimer's disease. Ann Neurol 1987; 21: 509-510.
18. Gibson GE, Sheu KF, and Blass JP. Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Transm 1998; 105: 855-870.
19. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106(34):14670-14675.
20. Hoshi M, Takashima A, Noguchi K, Murayama M, Sato M, Kondo S, Saitoh Y, Ishiguro K, Hoshino T, Imahori K. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase 3beta in brain. Proc Natl Acad Sci U S A 1996;93(7):2719-23.
21. Imahori K, Hoshi M, Ishiguro K, Sato K, Takahashi M, Shiurba R, Yamaguchi H, Takashima A, Uchida T. Possible role of tau protein kinases in pathogenesis of Alzheimer's disease. Neurobiol Aging 1998;19(1 Suppl):S93-98.
22. Gong CX, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 2008;15 (23):2321-2328.
23. Velliquette RA, O'Connor T, Vassar R. Energy inhibition elevates ß-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 2005;25:10874-10883.
24. O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, Eimer WA, Hitt B, Bembinster LA, Lammich S, Lichtenthaler SF, Hebert SS, De Strooper B, Haass C, Bennett DA, Vassar R. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 2008; 60: 988-1009.
25. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010; 9(6): 447-464.
26. Schwartz L, Abolhassani M, Guais A, Sanders E, Steyaert JM, Campion F, Israël M. A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results. Oncol Rep 2010; 23(5): 1407-1416.
27. Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, Engel J, Münch G. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther 2007; 113(1): 154-164.
28. Holness MJ, Sugden MC. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem Soc Trans 2003; 31 (Pt 6):1143-1151.
29. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003; 22; 423(6938): 435-439.
30. Serenó L, Coma M, Rodríguez M, Sánchez-Ferrer P, Sánchez MB, Gich I, Agulló JM, Pérez M, Avila J, Guardia-Laguarta C, Clarimón J, Lleó A, Gómez-Isla T. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009; 35 (3): 359-367.
31. Lee J, Kim MS. The role of GSK3 in glucose homeostasis and the development of insulin resistance. Diabetes Res Clin Pract 2007; 77 Suppl 1: S49-57.
32. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009; 156(6): 885-898.
33. Khanfar MA, Hill RA, Kaddoumi A, El Sayed KA. Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand-and structure-based virtual screening. J Med Chem 2010; 53(24): 8534-8545.
34. Wagman AS, Johnson KW, Bussiere DE. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 2004; 10(10):1105-1137.
35. Evin G, Kenche VB. BACE inhibitors as potential therapeutics for Alzheimer's disease. Recent Pat CNS Drug Discov 2007; 2(3): 188-199.
36. Albert JS. Progress in the development of beta -secretase inhibitors for Alzheimer's disease. Prog Med Chem 2009; 48: 133-161.
37. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-1562.
38. Wilcock GK, Black SE, Hendrix SB, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA; Tarenflurbil Phase II Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008; 7: 483-493.
39. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Phase 2-safety trial targeting amyloid beta production with a gammasecretase inhibitor in Alzheimer disease. Arch Neurol 2008; 65(8): 1031-1038.
40. Lilly Halts Development of Semagacestat for Alzheimer's disease based on preliminary results of Phase III Clinical Trials. Lilly Press release, Indianapolis, IN: Eli Lilly and Company, 17 August 2010. Available from: www.lilly.com(Last accessed 8 October 2010)
41. Parihar MS, Brewer GJ. Mitoenergetic failure in Alzheimer disease. Am J Physiol Cell Physiol 2007 Jan; 292(1):C8-23